Title | Spheroplast-Mediated Carbapenem Tolerance in Gram-Negative Pathogens. |
Publication Type | Journal Article |
Year of Publication | 2019 |
Authors | Cross T, Ransegnola B, Shin J-H, Weaver A, Fauntleroy K, VanNieuwenhze MS, Westblade LF, Dörr T |
Journal | Antimicrob Agents Chemother |
Volume | 63 |
Issue | 9 |
Date Published | 2019 09 |
ISSN | 1098-6596 |
Keywords | Amdinocillin, Anti-Bacterial Agents, Drug Tolerance, Enterobacter aerogenes, Enterobacter cloacae, Escherichia coli, Gram-Negative Bacterial Infections, Klebsiella pneumoniae, Meropenem, Microbial Sensitivity Tests, Spheroplasts |
Abstract | Antibiotic tolerance, the ability to temporarily sustain viability in the presence of bactericidal antibiotics, constitutes an understudied and yet potentially widespread cause of antibiotic treatment failure. We have previously shown that the Gram-negative pathogen can tolerate exposure to the typically bactericidal β-lactam antibiotics by assuming a spherical morphotype devoid of detectable cell wall material. However, it is unclear how widespread β-lactam tolerance is. Here, we tested a panel of clinically significant Gram-negative pathogens for their response to the potent, broad-spectrum carbapenem antibiotic meropenem. We show that clinical isolates of , , and , but not , exhibited moderate to high levels of tolerance of meropenem, both in laboratory growth medium and in human serum. Importantly, tolerance was mediated by cell wall-deficient spheroplasts, which readily recovered wild-type morphology and growth upon removal of antibiotic. Our results suggest that carbapenem tolerance is prevalent in clinically significant bacterial species, and we suggest that this could contribute to treatment failure associated with these organisms. |
DOI | 10.1128/AAC.00756-19 |
Alternate Journal | Antimicrob Agents Chemother |
PubMed ID | 31285232 |
PubMed Central ID | PMC6709500 |
Grant List | R01 AI143704 / AI / NIAID NIH HHS / United States R01 GM113172 / GM / NIGMS NIH HHS / United States |
Related Faculty:
Lars Westblade, Ph.D.